FDA Brief

Company record

Celularity, Inc

1 FDA warning letter since 2023 and 0 recalls in the last 12 months.

Get an email the day FDA posts anything new about Celularity, Inc.

Warning letters

  1. Celularity, Inc

    FDA warns Celularity that Interfyl is an unapproved new drug and unlicensed biological product marketed for orthopedic and wound uses.

    High risk